Chronic Hepatitis B (CHB) – Epidemiology Forecast to 2029

Hepatitis B is a liver disease caused by the hepatitis B virus (HBV). Hepatitis B is transmitted from person to person through blood, semen, and other body fluids (CDC, 2020; Mayo Clinic, 2020). Hepatitis B is a vaccine-preventable disease, but there is no cure if you have the disease. Chronic hepatitis B (CHB) occurs when the immune system cannot fight the infection and it remains in the body for six months or longer. CHB can be a life-threatening disease, and it is a major global health concern. Not all people with the infection will be symptomatic. In some people, CHB can develop into cirrhosis or liver cancer.

GlobalData epidemiologists used age- and sex-specific diagnosed prevalence rates to forecast the diagnosed prevalent cases. GlobalData epidemiologists applied country-specific diagnosed prevalence rates of CHB, wherever available, to each country’s population to obtain the number of estimated diagnosed prevalent cases. Diagnosed prevalent cases were also segmented by e-antigen status, HBV DNA level, ALT level, type of liver cirrhosis and co-infection with HIV or HCV.

The following data describes epidemiology of CHB cases. In 2019, the 9MM had 17,775,652 diagnosed prevalent cases of CHB. This is expected to increase to 18,133,860 cases by 2029, at an Annual Growth Rate (AGR) of 0.20%. The increase is driven by changes in the in the underlying population structure such as aging and population growth in the 9MM. In 2019, in each of the 9MM except China, the majority of diagnosed prevalent cases of CHB were negative for e-antigen. In the 9MM, China accounted approximately 90% of all diagnosed prevalent cases of CHB. The stagnant prevalence rate in the 9MM, is primarily due to the lifetime nature of the condition and to a large proportion of cases in the 9MM occurring in migrants from higher-risk countries who have missed the vaccination program in infancy.

Scope

The Chronic Hepatitis B Epidemiology Report and Model provide an overview of the risk factors and global trends of CHB in the nine major markets (9MM: US, France, Germany, Italy, Spain, UK, and Japan, Brazil and China).

This report also includes a 10-year epidemiological forecast for the following segmentations in all across the 9MM: diagnosed prevalent cases of CHB by age and sex; diagnosed prevalent cases of CHB by e-antigen status; diagnosed prevalent cases of CHB by HBV DNA level; diagnosed prevalent cases of CHB cases by ALT level; diagnosed prevalent cases of CHB by type of liver cirrhosis; diagnosed prevalent cases of CHB by co-infection with HIV or HCV.

The CHB epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.

The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The CHB Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global CHB market.

Quantify patient populations in the global CHB market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CHB therapeutics in each of the markets covered.

Understand magnitude of CHB population by e-antigen status, HBV DNA level, ALT level, type of liver cirrhosis and co-infection with HIV or HCV.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Chronic Hepatitis B: Executive Summary

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods

3.5 Epidemiological Forecast for CHB (2019-2029)

3.5.1 Diagnosed Prevalent Cases of CHB

3.5.2 Age-Specific Diagnosed Prevalent Cases of CHB

3.5.3 Sex-Specific Diagnosed Prevalent Cases of CHB

3.5.4 Diagnosed Prevalent Cases of CHB by HBeAg Status

3.5.5 Diagnosed Prevalent Cases of CHB by HBV DNA Level

3.5.6 Diagnosed Prevalent Cases of CHB by ALT Level

3.5.7 Diagnosed Prevalent Cases of CHB by Type of Liver Cirrhosis

3.6 Discussion

3.6.1 Epidemiological Forecast Insight

3.6.2 COVID-19 Impacts

3.6.3 Limitations of Analysis

3.6.4 Strengths of Analysis

4 Appendix

4.1 Bibliography

4.2 Primary Research – Prescriber Survey

4.3 About the Authors

4.3.1 Epidemiologist

4.3.2 Reviewers

4.3.3 Global Director of Therapy Analysis and Epidemiology

4.3.4 Global Head and EVP of Healthcare Operations and Strategy

4.4 About GlobalData

4.5 Contact Us

4.6 Disclaimer

List of Tables

Table 1: Summary of Newly Added Data Types and Countries

Table 2: Summary of Updated Data Types

Table 3: Risk Factors and Comorbidities for Chronic Hepatitis B

Table 4: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: 9MM, Diagnosed Prevalent Cases of CHB, Both Sexes, All Ages, 2019 and 2029.

Figure 2: 9MM, Diagnosed Prevalence of CHB (%), Both Sexes, All Ages, 2009-2019.

Figure 3: 9MM, Sources Used and Not Used for Diagnosed Prevalence of CHB (%)

Figure 4: 9MM, Sources Used for Diagnosed Prevalent Cases of CHB by HBeAg Status (N)

Figure 5: 9MM, Sources Used and Not Used for Diagnosed Prevalent Cases of CHB by HBV DNA Level (N)

Figure 6: 9MM, Sources Used for Diagnosed Prevalent Cases of CHB by ALT Level (N)

Figure 7: 9MM, Sources Used for Diagnosed Prevalent Cases of CHB by Type of Liver Cirrhosis (N)

Figure 8: 9MM, Diagnosed Prevalent Cases of CHB, Men and Women, All Ages, N, 2019

Figure 9: 9MM, Age-Specific Diagnosed Prevalent Cases of CHB, 9MM, Men and Women, All Ages, N, 2019

Figure 10: 9MM, Sex-Specific Diagnosed Prevalent Cases of CHB, All Ages, N, 2019

Figure 11: 9MM, Diagnosed Prevalent Cases of CHB by HBeAg Status, Men and Women, All Ages, N, 2019

Figure 12: 9MM, Diagnosed Prevalent Cases of CHB by HBV DNA Level, Men and Women, All Ages, N, 2019

Figure 13: 9MM, Diagnosed Prevalent Cases of CHB by ALT Level, Men and Women, All Ages, N, 2019

Figure 14: 9MM, Diagnosed Prevalent Cases of CHB by Type of Liver Cirrhosis, Men and Women, All Ages, N, 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports